139.Patel TP,Parekh RB,Moellering BJ,Prior CP.

1992.Different culture methods lead to differences in glycosylation of a murine IgG monoclonal anti-body.Biochem J285:839–845.

140.Kumpel BM,Rademacher TW,Rook GA,Williams PJ,Wilson IB.1994.Galactosylation of human IgG monoclonal anti-D produced by EBV-trans-formed B-lymphoblastoid cell lines is dependent on culture method and affects Fc receptor-mediated functional activity.Hum Antibodies Hybridomas5:143–151.

141.Lifely MR,Hale C,Boyce S,Keen MJ,Phillips J.

1995.Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions.Gly-cobiology5:813–822.

142.Kunkel JP,Jan DC,Butler M,Jamieson JC.2000.

Comparisons of the glycosylation of a monoclonal antibody produced under nominally identical cell culture conditions in two different bioreactors.

Biotechnol Prog16:462–470.

143.Serrato JA,Palomares LA,Meneses-Acosta A, Ramirez OT.2004.Heterogeneous conditions in dissolved oxygen affect N-glycosylation but not productivity of a monoclonal antibody in hybri-doma cultures.Biotechnol Bioeng88:176–188. 144.Hamako J,Matsui T,Ozeki Y,Mizuochi T,Titani parative studies of asparagine-linked sugar chains of immunoglobulin G from eleven mammalian p Biochem Phy-siol B106:949–954.

145.Raju TS,Briggs JB,Borge SM,Jones AJ.2000.

Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeu-tics.Glycobiology10:477–486.

146.Borrebaeck CK,Malmborg AC,Ohlin M.1993.

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer thera-peutics?Immunol Today14:477–479.

147.Jefferis R,Lund J.1997.Glycosylation of antibody molecules:Structural and functional significance.

Chem Immunol65:111–128.

148.Jefferis R,Lund J,Pound JD.1998.IgG-Fc-mediated effector functions:Molecular definition of interaction sites for effector ligands and the role of glycosylation.Immunol Rev163:59–76.

149.Matsuda F,Ishii K,Bourvagnet P,Kuma K,Haya-shida H,Miyata T,Honjo T.1998.The complete nucleotide sequence of the human immunoglobu-lin heavy chain variable region locus.J Exp Med 188:2151–2162.

150.Kawasaki K,Minoshima S,Nakato E,Shibuya K, Shintani A,Schmeits JL,Wang J,Shimizu N.

1997.One-megabase sequence analysis of the human immunoglobulin lambda gene locus.Gen-ome Res7:250–261.151.Schable KF,Zachau HG.1993.The variable genes of the human immunoglobulin kappa locus.Biol Chem Hoppe Seyler374:1001–1022.

152.Brensing-Kuppers J,Zocher I,Thiebe R,Zachau HG.1997.The human immunoglobulin kappa locus on yeast artificial chromosomes(YACs).

Gene191:173–181.

153.Kawasaki K,Minoshima S,Nakato E,Shibuya K, Shintani A,Asakawa S,Sasaki T,Klobeck HG, Combriato G,Zachau HG,Shimizu N.2001.Evo-lutionary dynamics of the human immunoglobulin kappa locus and the germline repertoire of the Vkappa genes.Eur J Immunol31:1017–1028. 154.Kaplan AP,Hood LE,Terry WD,Metzger H.1971.

Amino terminal sequences of human immunoglo-bulin heavy chains.Immunochemistry8:801–811. 155.Stoppini M,Bellotti V,Negri A,Merlini G,Garver F,Ferri G.1995.Characterization of the two unique human anti-flavin monoclonal immunoglo-bulins.Eur J Biochem228:886–893.

156.Akashi S,Kato K,Torizawa T,Dohmae N,Yama-guchi H,Kamachi M,Harada A,Imanaka T, Shimada I,Takio K.1997.Structural character-ization of mouse monoclonal antibody13-1against

a porphyrin derivative:Identification of a disulfide

bond in CDR-H3of Mab13-1.Biochem Biophys Res Commun240:566–572.

157.Dick LW Jr,Kim C,Qiu D,Cheng KC.2007.

Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibo-dies using model peptides.Biotechnol Bioeng97: 544–553.

158.Liu H,Gaza-Bulseco G,Sun J.2006.Character-ization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated tem-perature.J Chromatogr B Analyt Technol Biomed Life Sci837:35–43.(Epub2006Apr2027.)

159.Yu L,Vizel A,Huff MB,Young M,Remmele RL Jr, He B.2006.Investigation of N-terminal glutamate cyclization of recombinant monoclonal antibody in formulation development.J Pharm Biomed Anal 42:455–463.(Epub2006Jul2007.)

160.Chelius D,Jing K,Lueras A,Rehder DS,Dillon TM,Vizel A,Rajan RS,Li T,Treuheit MJ,Bon-darenko PV.2006.Formation of pyroglutamic acid from N-terminal glutamic acid in immunoglobulin gamma antibodies.Anal Chem78:2370–2376. 161.Ellison JW,Berson BJ,Hood LE.1982.The nucleotide sequence of a human immunoglobulin

C gamma1gene.Nucleic Acids Res10:4071–4079. 162.Harris RJ,Wagner KL,Spellman MW.1990.

Structural characterization of a recombinant CD4-IgG hybrid molecule.Eur J Biochem194: 611–620.

163.Harris RJ,Murnane AA,Utter SL,Wagner KL, Cox ET,Polastri GD,Helder JC,Sliwkowski MB.

1993.Assessing genetic heterogeneity in produc-tion cell lines:Detection by peptide mapping of a

DOI10.1002/jps JOURNAL OF PHARMACEUTICAL SCIENCES,VOL.97,NO.7,JULY2008

HETEROGENEITY OF MONOCLONAL ANTIBODIES2443